Related Experiment Video
Updated: Jan 25, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
Cedric Darini1, Nour Ghaddar1,2, Catherine Chabot1
1Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
Abstract:
Trastuzumab is integral to HER2+ cancer treatment, but its therapeutic index is narrowed by the development of resistance. Phosphorylation of the translation initiation factor eIF2α (eIF2α-P) is the nodal point of the integrated stress response, which promotes survival or death in a context-dependent manner. Here, we show an anti-tumor function of the protein kinase PKR and its substrate eIF2α in a mouse HER2+ breast cancer model. The anti-tumor function depends on the transcription factor ATF4, which upregulates the CDK inhibitor P21CIP1 and activates JNK1/2. The PKR/eIF2α-P arm is induced by Trastuzumab in sensitive but not resistant HER2+ breast tumors. Also, eIF2α-P stimulation by the phosphatase inhibitor SAL003 substantially increases Trastuzumab potency in resistant HER2+ breast and gastric tumors. Increased eIF2α-P prognosticates a better response of HER2+ metastatic breast cancer patients to Trastuzumab therapy. Hence, the PKR/eIF2α-P arm antagonizes HER2 tumorigenesis whereas its pharmacological stimulation improves the efficacy of Trastuzumab therapy.
Insights
The PKR/eIF2α-P pathway fights HER2+ cancers. Stimulating this pathway with SAL003 enhances Trastuzumab effectiveness in resistant breast and gastric tumors, improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Trastuzumab is a key treatment for HER2+ cancers, but resistance limits its efficacy.
- The integrated stress response, regulated by phosphorylated eukaryotic initiation factor 2 alpha (eIF2α-P), influences cancer cell survival.
- Understanding resistance mechanisms is crucial for improving HER2+ cancer therapy.
Purpose of the Study:
- To investigate the anti-tumor role of the PKR/eIF2α-P pathway in HER2+ breast cancer.
- To explore the potential of targeting this pathway to overcome Trastuzumab resistance.
- To correlate eIF2α-P levels with patient response to Trastuzumab therapy.
Main Methods:
- Utilized a mouse model of HER2+ breast cancer.
- Examined the induction of the PKR/eIF2α-P pathway by Trastuzumab in sensitive and resistant tumors.
- Assessed the effect of the phosphatase inhibitor SAL003 on Trastuzumab efficacy in resistant models.
- Analyzed the prognostic value of eIF2α-P in HER2+ metastatic breast cancer patients.
Main Results:
- Demonstrated an anti-tumor function for the PKR/eIF2α-P pathway, dependent on ATF4, P21CIP1, and JNK1/2.
- Found that Trastuzumab induces the PKR/eIF2α-P pathway in sensitive, but not resistant, HER2+ tumors.
- Showed that SAL003 enhances Trastuzumab potency in resistant HER2+ breast and gastric tumors.
- Correlated higher eIF2α-P levels with improved patient response to Trastuzumab in metastatic breast cancer.
Conclusions:
- The PKR/eIF2α-P pathway acts as a tumor suppressor in HER2+ cancers.
- Pharmacological stimulation of eIF2α-P phosphorylation can overcome Trastuzumab resistance.
- eIF2α-P is a potential biomarker for predicting Trastuzumab treatment response.
More Related Videos
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Responses to Heat and Cold Stress
Responses to Salt Stress
Stress Response System
Alarm stage
In the alarm stage, the body's...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Psychological Responses to Stress
Other Stress Responses in Bacteria